Prozac pre-patent push
Executive Summary
Lilly will build its U.S. sales force to 2,600 by mid-year to extend promotions of the antidepressant Prozac and the antipsychotic Zyprexa and to initiate launch of Lilly/Takeda's antidiabetic Actos, under review at FDA. Lilly's pipeline includes several new Prozac products: a once-weekly formulation is in Phase III, a combination with Zyprexa is in Phase II, and the company awaits Federal Trade Commission approval of its agreement to license a single-isomer version of fluoxetine from Sepracor (1"The Pink Sheet" March 15, p. 3)